TREACE MEDICAL CONCEPTS INC

For the period ended Jun 30, 2024. Filed Aug 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 6, 2024

TMCI$4.88+2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Revenue	$44,455	$41,953	$95,563	$84,148
Cost of goods sold	8,781	7,675	18,908	15,714
Gross profit	35,674	34,278	76,655	68,434
Operating expenses
Sales and marketing	37,681	33,773	78,009	67,428
Research and development	5,157	3,526	10,416	6,938
General and administrative	14,218	10,031	28,580	20,896
Total operating expenses	57,056	47,330	117,005	95,262
Loss from operations	(21,382)	(13,052)	(40,350)	(26,828)
Interest income	1,376	1,968	2,911	3,447
Interest expense	(1,312)	(1,282)	(2,629)	(2,567)
Other income, net	112	95	186	223
Other non-operating income (expense), net	176	781	468	1,103
Net loss	$(21,206)	$(12,271)	$(39,882)	$(25,725)
Other comprehensive income (loss)
Unrealized gain (loss) on marketable securities	(95)	(163)	(189)	(192)
Comprehensive loss	$(21,301)	$(12,434)	$(40,071)	$(25,917)
Net loss per share attributable to common stockholders, basic and diluted	$(0.34)	$(0.20)	$(0.64)	$(0.43)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted	62,081,494	61,382,514	61,937,140	60,060,483

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.